Virtual Library

Start Your Search

Jenny G. Turcott



Author of

  • +

    MA02 - Improving Outcomes for Patients with Lung Cancer (ID 895)

    • Event: WCLC 2018
    • Type: Mini Oral Abstract Session
    • Track: Advanced NSCLC
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 10:30 - 12:00, Room 201 BD
    • +

      MA02.08 - The Effect of Nabilone on Appetite, Nutritional Status, and Quality of Life in Lung Cancer Patients: A Randomized, Double-Blind Clinical Trial (ID 13428)

      11:15 - 11:20  |  Presenting Author(s): Jenny G. Turcott

      • Abstract
      • Presentation
      • Slides

      Background

      Over one half of the patients diagnosed with advanced lung cancer experience anorexia. In addition to its high incidence, cancer-induced anorexia promotes the development of the anorexia-cachexia syndrome, which is related to poor clinical outcomes. Recently, drugs derived from cannabinoids, such as Nabilone, have been recognized for their appetite improvement properties; however, clinical trials to support their use in cancer patients are necessary.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      This is a randomized, double-blind, placebo-controlled clinical trial to assess the effect of Nabilone vs. placebo on the appetite, nutritional status, and quality of life in patients diagnosed with advanced Non-small cell lung cancer (NSCLC) (NCT02802540).

      4c3880bb027f159e801041b1021e88e8 Result

      A total of 65 patients from the outpatient clinic at the National Institute of Cancer (INCan) were assessed for eligibility and 47 were randomized to receive Nabilone (0.5 mg/2 weeks followed by 1.0 mg/6 weeks) or placebo. After 8 weeks of treatment, patients who received Nabilone increased their energy intake (342-kcal) and had a significantly improvements in Quality of life parameters.

      diapositiva1.jpgdiapositiva1.jpg

      8eea62084ca7e541d918e823422bd82e Conclusion

      Nabilone is an adequate and safe therapeutic option to aid in the treatment of patients diagnosed with anorexia. Larger trials are necessary in order to draw robust conclusions in regard to its efficacy in lung cancer patients.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.01-96 - Dysgeusia Associated with Nutritional and Quality of Life Parameters in Non-Small Cell Lung Cancer Patients Naïve to Chemotherapy (ID 13369)

      16:45 - 18:00  |  Presenting Author(s): Jenny G. Turcott

      • Abstract
      • Slides

      Background

      Dysgeusia (taste alteration) has been reported in more than 50% of patient undergoing chemotherapy, however, it can be present before treatment, and it can be associated with nutritional and quality of life parameters.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We evaluated 65 patients naïve to chemotherapy, the alteration of taste by self-reporting questionnaire and through rinse stimuli to identify detection and recognition thresholds of umami, sweet and bitter taste; as well as, their association with nutritional and quality of life parameters.

      4c3880bb027f159e801041b1021e88e8 Result

      Dysgeusia, perceived as a different taste from food was reported in 35% of patients. Those with dysgeusia presents less mean of weight (p=0.059), less lean body mass (p=0.027), higher Fat Mass (p= 0.027), less consumption of protein (0.059), iron (0.022) and sodium (0.034). Patients with dysgeusia reported unfavorable score in functional scales of Health Related Quality of Life (HRQL), than those without dysgeusia; including, Role Functioning (p=0.182*), emotional functioning (p=0.038), cognitive functioning (p=0.017) and social functioning (0.325*). And, the same for symptomatic scales: fatigue (p=0.016), nausea and vomiting (p=0.021), pain (p=0.133*), appetite loss (p<0.001) and constipation (p=0.005).

      diapositiva1.jpgdiapositiva2.jpg

      8eea62084ca7e541d918e823422bd82e Conclusion

      Conclusion: Patients with non-small cell lung cancer present dysgeusia before treatment and affect clinical parameters, food consumption habits and quality of life. Nutritional- care must be provided opportunely.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.